Kinetics of INF-γ Production in Intensive Care Patients

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Aug 9, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how a treatment called interferon gamma (IFN-γ) can help improve the immune system of patients in intensive care. Many patients who are admitted to the ICU after severe injuries, major surgeries, or serious breathing problems experience a weakened immune response, making them more susceptible to infections and other complications. The goal of the trial is to find out if monitoring the levels of IFN-γ in the blood can help identify the right patients who might benefit from this treatment at the right time.

To participate in this study, patients must be 18 years or older and admitted to the ICU due to severe trauma, breathing difficulties, or specific types of surgeries. Unfortunately, pregnant women and those with very low hemoglobin (a protein in blood that carries oxygen) cannot join. Participants will undergo a simple blood test that quickly measures their immune system's response, and this information will help doctors understand how to better support patients in the ICU. It's important to note that the study is not yet recruiting participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged 18 years or older
• • Patients admitted to intensive care after severe trauma, or presenting with acute respiratory distress, or undergoing cardiac, vascular, or digestive surgery with planned postoperative intensive care. Exclusion Criteria
• Exclusion Criteria:
• • Expressed opposition from the patient, a relative (if applicable), or their legal representative (guardian, curator)
• • Pregnant woman
• • Hemoglobin less than 7g/dl at inclusion